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Abstract
The multidimensional nature of obsessive-compulsive disorder (OCD) has been consistently reported. Clinical and
biological characteristics have been associated with OCD dimensions in different ways. Studies suggest the existence
of specific genetic bases for the different OCD dimensions. In this study, we analyze the genomic markers, genes, gene
ontology and biological pathways associated with the presence of aggressive/checking, symmetry/order,
contamination/cleaning, hoarding, and sexual/religious symptoms, as assessed via the Dimensional Yale-Brown
Obsessive Compulsive Scale (DY-BOCS) in 399 probands. Logistic regression analyses were performed at the single-
nucleotide polymorphism (SNP) level. Gene-based and enrichment analyses were carried out for common (SNPs) and
rare variants. No SNP was associated with any dimension at a genome-wide level (p < 5 × 10−8). Gene-based analyses
showed one gene to be associated with hoarding (SETD3, p= 1.89 × 10−08); a gene highly expressed in the brain and
which plays a role in apoptotic processes and transcriptomic changes, and another gene associated with aggressive
symptoms (CPE; p= 4.42 × 10−6), which is involved in neurotrophic functions and the synthesis of peptide hormones
and neurotransmitters. Different pathways or biological processes were represented by genes associated with
aggressive (zinc ion response and lipid metabolism), order (lipid metabolism), sexual/religious (G protein-mediated
processes) and hoarding (metabolic processes and anion transport) symptoms after FDR correction; while no pathway
was associated with contamination. Specific genomic bases were found for each dimension assessed, especially in the
enrichment analyses. Further research with larger samples and different techniques, such as next-generation
sequencing, are needed to better understand the differential genetics of OCD dimensions.
Background
Obsessive-compulsive disorder (OCD) is a neu-
ropsychiatric condition that has an estimated prevalence of
2–3%1. Despite the unitary nosological status of OCD
(DSM-5), considerable heterogeneity of OCD symptoms
exists. Several studies have looked into different symptom
dimensions present in OCD; some have reported explora-
tory or confirmatory factor analysis based on Yale-Brown
Obsessive Compulsive Scale Checklist (Y-BOCS-CL) items.
Most of those studies have reported four or five main
(second-order) factors, which in part depend on the
methodology employed2,3, thereby suggesting a multi-
dimensional model for OCD. This multidimensional nature
of OCD has been confirmed by meta-analyses and sys-
tematic reviews4,5. Along these lines, specific instruments
such as the Dimensional Yale-Brown Obsessive Compulsive
Scale (DY-BOCS6;) have been developed to assess OCD
severity in different symptom dimensions.
A range of clinical characteristics has been associated
with OCD symptom dimensions in different ways. In this
vein, it has been proposed that the hoarding and sym-
metry dimensions are characteristic of an early-age OCD
group7,8. In terms of comorbidities, a factor comprising
aggressive, sexual and religious symptoms has been
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associated with comorbid major depressive disorder and
bipolar disorder (MDD/BD); while patients with sym-
metry/order symptoms show greater comorbidity with
eating and addictive disorders as well as attention-deficit/
hyperactivity disorder (ADHD)9. Meanwhile, the con-
tamination/cleaning dimension has been reported as the
dimension that is least frequently associated with any
other Axis I disorder10. In addition, the hoarding and
symmetry/order dimensions have been associated with a
poorer response to pharmacological treatment8,10.
Differential endophenotypic profiles have also been
reported in relation to symptom dimensions in neuroi-
maging studies. For instance, OCD probands with sym-
metry/order symptoms have been reported to present a
reduced volume of the right precentral gyrus11 and the
hippocampus, which is also associated with aggressive/
checking symptoms when compared to healthy controls12.
In addition, the aggressive/checking and contamination/
cleaning dimensions have been negatively correlated to
right cerebellum and right insula volumes, respectively13.
In terms of functionality, patients with aggressive/check-
ing and sexual/religious symptoms have been found to
present greater amygdala activation when confronted by
fear-inducing stimuli14. Also, differences in connectivity
have been observed between the aggressive/checking,
sexual/religious and hoarding dimensions15. Although we
do not know to what extent these observed neurological
differences between the OCD dimensions have a genetic
basis, some of the structural and functional brain char-
acteristics identified have been directly related to certain
genetic variants in OCD patients as well as in those with
other psychiatric disorders16–20.
In fact, specific genetic bases have been identified for
the different OCD symptom dimensions. For instance,
severity of the contamination/cleaning dimension has
been associated with both the Met allele of the Vall66Met
locus within the brain-derived neurotrophic factor gene
(BDNF)21 and the c.256G allele of the 5-
hydroxytryptamine receptor 3E (HTR3E) variant
rs762761522. The presence of this dimension has also
been associated with the variants rs4657411 within the
LIM homeobox transcription factor 1 alpha gene
(LMX1A), and rs2075507 of the catechol-O-methyltran-
spherase gene (COMT) in women23,24. In addition, a
protective role against these dimensions has been attrib-
uted to the ACCCG haplotype of the estrogen receptor 1
gene (ESR1)25. The symmetry/order dimension has been
related to the S allele and the SS genotype of the serotonin
transporter polymorphic region (SERTPR)26; the presence
of the 2R allele within the dopamine receptor D4 gene
(DRD4) 48-bp variable number of tandem repeats poly-
morphism (VNTR)27; and the A allele in the COMT
variant rs2075507 in men24. This dimension in combi-
nation with aggressive/checking behavior has been
associated with specific variants in a promoter region of
the glutamate ionotropic receptor NMDA-type subunit
2B gene (GRIN2B) (rs1019385)28 and the SLIT and
NTRK-like family member 1 gene (SLITRK1) (rs9593835);
the latter, specifically in men23. The SERTPR has also
been associated with higher scores in a religious/somatic
dimension (l/s and l/l genotypes)29 and in counting and
repeating rituals in OCD patients with a comorbid tic
disorder (l/l genotype)30. Women who exhibit hoarding
symptoms have been reported to present a higher fre-
quency of the Met/Met genotype of the COMT variant
rs4680 than those who do not. Hoarding has also been
associated with a variant (rs1017412) within the neuro-
trophic receptor tyrosine kinase 3 gene (NTRK)31 and
with both the short variant of the serotonin-transporter-
linked polymorphic region (5HTTLPR), and its long
variant together with the G allele at rs25531 in males32. A
neutralization dimension, as assessed by the Obsessive-
Compulsive Inventory-Revised (OCI-R) has been asso-
ciated with a variant of LMX1A (rs4657411)23. Severity
scores in a dimension comprising somatic and sensory
phenomena symptoms have shown a trend towards an
association with the Val58Met genotype of the COMT
gene in interaction with sex, with women presenting
lower scores33.
Although a large number of studies have focused on
elucidating the genetic basis of OCD, inconsistent results
have been reported in most respects34. A possible expla-
nation for this is that the studies do not usually consider
different symptom profiles among OCD patients. It has
consistently been argued that it is necessary to account for
OCD heterogeneity in genetic and neurobiological stu-
dies35,36. Therefore, in this study, we analyze the variants,
genes and functional pathways that might be differentially
involved in the OCD dimensions measured by the DY-
BOCS6 through an exploratory genomic method. We
hypothesize that different genomic bases will be found for
the different OCD dimensions.
Methods
Subjects
Three hundred and ninety-nine Caucasian Spanish
patients (n= 399; 210 women; mean age= 35 ± 11) with
an OCD diagnosis were recruited from the OCD clinic at
Bellvitge Hospital (Barcelona, Spain). Diagnoses were
made by three psychiatrists with extensive clinical
experience in OCD, following the DSM-IV criteria for
OCD diagnosis37 using the Structured Clinical Interview
for DSM-IV Axis I Disorders-Clinician Version
(SCIDCV)38. All the patients had the disorder for at least
one year. Those patients presenting psychoactive sub-
stance abuse/dependence (current or in the past six
months), psychotic disorders, intellectual disability, severe
organic or neurological pathology (except tic disorders),
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or autism spectrum disorders were excluded from the
study. Other affective and anxiety disorders were not
criteria for exclusion in cases where OCD was the main
diagnosis.
Participants were required to give written consent after
being fully informed about the study. The study was
approved by the Ethical Committees of Bellvitge Hospital
and was performed in accordance with the Helsinki
Declaration of the World Medical Association.
Clinical assessment
Medical data and both sociodemographic and clinical
characteristics were collected via a structured interview
during each patient’s first appointment at the clinic.
Age at onset was defined as the moment when obsessive
symptoms reached a clinically significant level. Family
psychiatric history was considered dichotomously, but
specific information regarding family history of OCD,
Tourette syndrome and depression was also collected.
Only family members who had received a formal diag-
nosis were considered to be affected.
Baseline severity of obsessive and compulsive symptoms was
also assessed through the clinician-administered version of the
Y-BOCS39 during the patient’s first visit to the clinic. A global
measure, as well as independent measures for both obsessions
and compulsions, were recorded.
OCD Dimension: presence and severity
Dimension-specific presence and severity were eval-
uated using the DY-BOCS6, which is composed of a self-
report part and a clinician-rated instrument. It assesses
OCD severity in six different symptom dimensions that
gather together thematically similar symptoms. The six
are: aggressive obsessions and checking compulsions
(aggressive/checking); symmetry obsessions and order
compulsions (symmetry/order); contamination obsessions
and cleaning/washing compulsions (contamination/
cleaning); hoarding obsessions and compulsions (hoard-
ing); sexual or religious obsessions accompanied by dif-
ferent rituals (sexual/religious); and a miscellaneous
dimension including other obsessive thoughts and com-
pulsive behavior (miscellaneous). We did not consider this
last dimension in our analyses given its lack of specificity.
Genotyping data and quality control
Our sample consisted of 399 OCD patients genotyped
using the Infinium PsychArray-24 BeadChip from Illu-
mina. This array was developed in collaboration with the
Psychiatric Genomics Consortium (PGC) and includes
50,000 variants associated with common psychiatric dis-
orders. Variant calling was performed using three differ-
ent algorithms: GenCall, which is Illumina’s default
calling algorithm, and Birdseed, both for common
variants; and zCall, aimed at rare variant calling. A unique
set of genotypes was derived from a consensus merge of
the GenCall and Birdseed common variants, also includ-
ing rare variants called by zCall that passed quality control
(QC) from the consensus merge of GenCall and Birdseed.
QC filtering of genotype data was performed using
PLINK40. Only non-monomorphic autosomal biallelic
variants in Hardy Weinberg equilibrium (p < 0.0001) with
a call rate of above 98% were included.
Samples that had a call rate lower than 98% were
removed. Identity by descent was calculated using inde-
pendent SNPs, and omitting those samples with a pi-hat
greater than 0.241. Population stratification was tested by
principal component analysis, removing those samples
that deviated by more than 5 standard deviations (SDs)
from the mean in the first two components.
Statistical analysis
Association analyses at the SNP level were performed
using the GenABEL library for R software42. Regression
analyses were carried out under a log-additive model (in
which the genotypes were coded as 0, 1 or 2 depending on
the number of minor alleles). These operations were
performed for autosomal SNPs (markers showing a minor
allele frequency (MAF) > 0.05 in autosomes). Given the
non-normality of the DY-BOCS scores and the impossi-
bility of normalizing them, these variables were dichot-
omized to analyze the presence/absence of the different
DY-BOCS dimensions. A logistic regression analysis was
performed for each dimension, with the dependent
variable being the dimension we were testing. Age, sex,
and the four other dimensions were included as covari-
ates in all the models. Linkage-disequilibrium (LD) plots
were designed using the LocusZoom software, based
on 1000 genome CEU population data (hg19/1000 Gen-
omes Mar 2012 EUR)43. For SNP annotation, we used
the Infinium PsychArray Gene Annotation File provided
by Illumina (https://support.illumina.com/downloads/
infinium-psycharray-product-support-files.html).
Power calculations were performed with Genetic Asso-
ciation Study Power Calculator software (http://csg.sph.
umich.edu/abecasis/cats/gas_power_calculator/reference.
html) to determine the power of our study to detect
associations considering our sample size.
Gene-based association analyses were performed via the
Sequence Kernel Association Test (SKAT)44 using the
SKATMeta library45 for R software. This type of gene-
based analysis has the advantage of including rare var-
iants, which were not considered in SNP-based analyses
given the lack of statistical power for detecting associa-
tions with these variants at a single-variant level. SKAT
combines the effects of common and rare variants in
gene-sets, increasing the power to detect small effects.
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Only results from genes with at least two genotyped
markers were considered. A false discovery rate (FDR)
correction was used as a significance criterion.
Finally, enrichment analyses were performed for genes
with at least two genotyped markers that had a SKAT p-
value lower than 0.01 using web-accessible DAVID
(Database for Annotation, Visualization, and Integrated
Discovery) Bioinformatic Resources v6.846,47. This soft-
ware analyzes input genes in the context of a genomic
background (in this study, we selected the entire human
genome as background) to cluster genes enriched in
biological pathways and gene ontologies. We ordered the
reported results by the FDR statistic to prioritize for
further interpretation.
Results
Subjects and genotyping quality control
Three hundred and seventy-six (n= 376) samples pas-
sed quality control procedures. Table 1 summarizes the
sociodemographic and clinical data including DY-BOCS
scores gathered for the final OCD sample.
SNP-level association analyses
Our total dataset consisted of 338,357 autosomal mar-
kers, of which 258,937 were SNPs (MAF ≥ 0.05).
No SNP exceeded the statistical threshold for genome-
wide significance (p < 5 × 10−8) in any dimension (Fig. 1).
The results at a p value ≤ 10−4 for the five dimensions can
be seen in Table 2. Suggestive associations (p < 10−5) were
found with the aggressive, contamination, order, and
hoarding dimensions (Fig. 1a–d).
In the order dimension, eight variants presented sug-
gestive associations (p < 10−5). Six of these variants were
within chromosome 12 and, given the proximity between
them (5 of them were variants of the IPO8 gene), we
performed LD analysis on this region. We found two
clusters of SNPs: (1) rs7316477 (1.50 × 10−6), rs14139
(1.50 × 10−6), rs6487927 (1.58 × 10−6) and rs10771752
(1.83 × 10−6), all exonic variants located in the IPO8
(Importin 8) gene (Fig. 2a); and (2) rs6487928 (2.99 ×
10−6) and rs12146709 (3.70 × 10−6), exonic variants
located in IPO8 and CAPRIN2 (Caprin Family Member 2),
respectively (Fig. 2b). All these markers should be con-
sidered as forming a single association peak, since the
level of association was not maintained for any of them
when adjusting the model for each of the other markers.
Gene-based association analyses
Gene-based analysis were performed for 22,017 (aggressive),
21,179 (order), 20,466 (contamination) and 22,472 (hoarding
and sexual/religious) genes. Of these, 17,001 (aggressive),
16,467 (order), 15,790 (contamination), and 17,378 (hoarding
and sexual/religious) had at least two genotyped markers and
were considered in our further analyses.
Our results for genes with at least a suggestive asso-
ciation (p < 10−4) in the five dimensions can be seen in
Table 3. One gene reached genome-wide significant
association with hoarding (SET Domain Containing 3,
Actin Histidine Methyltransferase, SETD3; p= 1.89 ×
10−08). This gene codes for a protein involved, among
other functions, in actin binding and modification, his-
tone methylation, chromatin organization, and regula-
tion of transcription48. The second most significant gene
was CPE (Carboxypeptidase E), which reached genome-
wide significant association with the aggressive dimen-
sion (p= 4.42 × 10−6). This gene codes for a membrane
protein involved in the synthesis of peptide hormones
and neurotransmitters as well as different neurotrophic
functions49.
Table 1 Sociodemographic and clinical characteristics of
the sample of 376 OCD patients.
Age, years 35.2 ± 10.7 (18–71)
Male/Female 186/190 (49.5/ 50.5)
Age at onset of OCD 19.9 ± 8.9 (4–46)a
Y-BOCS score
Global 25.8 ± 5.5 (9–40)
Obsessions 12.6 ± 3.6 (0–20)
Compulsions 12.3 ± 4.0 (0–20)
Baseline HDRS score 12.2 ± 6.0 (0–29)
Current comorbidity
No comorbidity 212 (56.4)
Mood disorder 71 (18.9)
Tics 52 (13.8)
Eating disorders 19 (05.1)
Presence of dimensions in worst-ever period
Aggresive/checking 278 (73.9)
Symmetry/ordering 162 (43.1)
Contamination/cleaning 172 (45.7)
Hoarding 91 (24.2)
Sexual/religious 95 (25.3)
Family psychiatric history
No psychiatric diagnosis 138 (36.7)
OCD 81 (21.5)
Mood disorder 114 (30.3)
Tics/ Tourette sydrome 35 (9.3)
Data are mean ± SD (range) or percentage (%).
OCD obsessive compulsive disorder, Y-BOCS Yale-Brown Obsessive Compulsive
Scale, HDRS Hamilton Depression Rating Scale.
aAge at onset was collected for 374 patients (n= 374).
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Functional annotation
Functional annotation was gathered for a final set of 154
(aggressive), 103 (contamination), 111 (order), 196
(hoarding) and 167 (sexual/religious) genes. The thresh-
old used to select the genes included in the enrichment
analyses (p < 0.01) included 1% of the genes in all the
dimensions except the hoarding dimension, for which 2%
of the genes presented a p-value lower than 0.01.
Detailed information on the results of these analyses are
given in Tables 4 and 5. In the case of the hoarding
dimension, the different pathways obtained are clustered
in two groups according to their biological similarity.
Discussion
In this study, we examined the genomic bases of each of
the most consistently validated symptom dimensions of
OCD. Differential findings were obtained for the five
dimensions considered. At the SNP-level, no variant
reached genome-wide significance. The top SNPs were six
markers in the order dimension (forming a single asso-
ciation peak) and one variant in the hoarding dimension
(p < 5 × 10−6). Gene analyses showed one gene associated
with hoarding (SETD3, p= 1.89 × 10−8) and another with
the aggressive dimension (CPE, p= 4.42 × 10−6) at a
genome-wide level. Different pathways or biological pro-
cesses were represented by the aggressive, order, sexual/
religious, and hoarding dimensions. For contamination,
no pathway remained associated after FDR correction.
Six of the top variants at the SNP-level analysis con-
formed a genomic region involving IPO8 and CAPRIN2,
which presented an association signal with the order
dimension. Certain intergenic variants near CAPRIN2
presented association signals (p < 5 × 10−5) with different
neuropsychological variables and personality traits
(https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000342.v18.p11; https://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000338.v1.p1). Considering the LD findings
for this region and the fact that the six variants represent a
single peak of association, it may be interesting to consider
this genomic region in further studies, since it could be a
relevant for the order dimension.
Gene-based analyses reported one gene associated with
hoarding at the genome-wide significance level (SETD3,
p= 1.89 × 10−8). That gene is expressed in brain regions
associated with OCD50,51 such as caudate and cere-
bellum (The Human Protein Atlas, SETD3, gene avail-
able from https://www.proteinatlas.org/ENSG000001835
76-SETD3/tissue) and seems to mediate transcriptome
changes in the hypothalamus of mice52. It has also been
associated with apoptotic processes, which in turn have
been observed to mediate the neuronal loss in certain brain
regions of BD patients53. Although two SNPs located near
SETD3 show suggestive associations with autoimmune and
Fig. 1 Manhattan plots for the genome-wide association analyses
of genetic variations and OCD dimensions. a Aggressive
dimension. b Contamination dimension. c Order dimension. d
Hoarding dimension. e Sexual/religious dimension. A blue line
indicates the level of suggestive evidence of association (p < 1 × 10−5).
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inflammatory conditions (rs2614463, P= 7.00 × 10−6;
rs2664299, P= 9.00 × 10−6), none of them are in LD with
any of the SETD3 variants in our analysis—rs12886549
(P= 0.68, MAF= 0.24, OR= 1.09); rs8015827 (P= 0.79;
MAF= 0.39; OR= 1.05); rs34322735 (P= 1.72 × 10-08,
MAF= 0.01, OR= 101.39). CPE, which was associated with
the aggressive dimension, is a gene highly expressed in
brain54. Different polymorphisms in this gene have been
associated with a loss of neuroprotective function by
reducing the effects of the oxidative stress in human cell
lines55 and transgenic mice56, leading to memory deficits
and depressive behavior56. In addition, CPE-knockout mice
have shown neurodegeneration in the hippocampus and the
prefrontal cortex57.
In relation to the aggressive dimension, enrichment
analyses showed overrepresentation in response to zinc
ions (GO:0010043, FDR= 0.002). Zinc ions are highly
prevalent in the brain, being especially prominent in
forebrain glutamatergic neurons, the hippocampus, and
the amygdala58,59, and they plays an important role in
neuronal plasticity60. Zinc deficiency has been associated
with cognitive decline, Alzheimer’s disease (AD) and
Fig. 2 Regional association plots with LD reported for Order dimension-suggestively associated (p < 10-5) single-nucleotide
polymorphisms (SNPs) in chromosome 12. a Plot of rs7316477. b Plot of rs6487928.
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different psychiatric disorders in the elderly. In addition,
genetic variants within ZNF142, a gene coding for a zinc-
finger protein, have been associated with a neurodeve-
lopmental disorder resulting in speech impairment and
intellectual disability61. The Peroxisomal lipid metabolism
pathway (R-HSA-390918) was also significantly enriched
in the aggressive dimension. Lipid metabolism has been
extensively associated with different neuropsychiatric
disorders, such as BD and depressive disorders, as well as
AD62–65. Similarly, the sphingolipid signaling pathway
(hsa04071) appears overrepresented in the order dimen-
sion. Sphingolipids are structural elements of cellular
membranes and they play a role in cell signaling, differ-
entiation and proliferation, apoptotic processes and
inflammation66. Sphingolipid signaling has been observed
to be involved in anxiety-like behavior in animal models
as well as schizophrenia, depression and BD66–69.
Sexual/religious dimension genes were found enriched
for G alpha (12/13) signaling events (R-HSA-416482).
G12/13 subunits are alpha units of heterotrimeric G
proteins that regulate different cell processes through the
use of guanine nucleotide exchange factors (GEFs). This
family of G-protein subunits has been associated with
neurodevelopment and is involved in processes of cell
proliferation and migration70. In addition, G12 subunits
have been observed to influence memory consolidation
and contextual retrieval in mice, via increased expression
in the hippocampus71. Ta
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Table 3 Best gene-based results from SKAT analyses for
the different OCD dimensions.
Gene P QMETA CMAF NSNPS
Aggressive
CPE 4.42 × 10−06 10 857.8 4.18 15
HIST1H2AH 5.13 × 10−05 9 329.72 0.03 2
FOXP4 1.01 × 10−05 11 790.03 1.48 8
CREB5 9.29 × 10−05 6 440.17 2.87 12
Order
PPP2R2D 6.54 × 10−05 23.49 0.65 3
Hoarding
SERINC2 8.17 × 10−05 10 941.25 0.26 9
SETD3 1.89 × 10−08 16 579.98 0.64 3
Sexual/Religious
CDC42BPA 4.97 × 10−05 7 002.15 6.61 27
GPR137B 3.65 × 10−05 18 669.76 2.24 15
LYZL4 3.48 × 10−05 9 965.91 0.07 3
ABR 9.13 × 10−05 7 283.78 1.81 7
CMAF collected minor allele fruequency, QMETA test score reported by SKAT.
Bold text highlights significant associations at a gene-based analysis level.
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For the hoarding dimension, the first cluster of biolo-
gical mechanisms and pathways includes cellular meta-
bolic processes, such as lipid, vitamin and carbohydrate
metabolism, all involving glucuronidation processes, as
most genes included in these mechanisms or pathways
code for UDP-glucuronosyltransferases (Table 5). It has
been demonstrated that an alteration of the activity of
these enzymes can affect brain function72. As an example,
induction of UDP-glucuronosyltransferase 1A1 during the
prenatal period can cause neurodevelopmental disorders
in mice73.
There is increasing evidence from metabolomic studies
of the importance of metabolic processes in psychiatric
disorders. Post-traumatic stress disorder (PTSD) has been
associated with the alteration of different kinds of meta-
bolites, such as monosaccharides, nucleosides or fatty
acids74. Furthermore, there is evidence of dysfunctional
metabolism of lipids and vitamins in depressed patients75,
which may explain the high prevalence of comorbid
metabolic syndrome and cardiovascular disease76.
A lower plasma concentration of certain lipids with a
neuroprotective role also has been observed in PTSD
patients, compared to healthy controls77. Altered lipid
metabolism has been found in other psychiatric condi-
tions, such as MDD, BD or schizophrenia, and associated
with symptoms including anxiety, stress and cognitive
impairment78. Lipid metabolism in turn influences steroid
synthesis, which has been associated with brain electrical
activity through the role of lipids in modulating neuronal
excitability79. In addition, an alteration of porphyrin and
chlorophyll metabolism might affect the formation of
heme groups, possibly leading to neurotoxic effects,
among others80,81.
The second cluster of biological mechanisms and
pathways for the hoarding dimension is related to anion
transport. Most of the hoarding dimension genes involved
are members of the solute-carrier 26 family A (SLC26A).
These transporters have been observed to influence,
among other functions, microbiome composition, pH
regulation, and anion transport82, which in turn have been
related with the pathophysiology of different psychiatric
disorders83. More specifically, anion transport and pH
regulation in the brain play a role in intra- and inter-
signaling and plasticity processes84. In relation to micro-
biome composition, late-onset autism has been associated
with differences in the gastrointestinal microflora when
compared to healthy controls85. Moreover, exposure to
certain microbial pathogens during fetal development has
been associated with the pathogenesis of schizophrenia in
humans86, and both anxiety-like behavior and cognitive
impairment in rodents87,88. It is interesting to note the
increase in the genetic weight observed in the hoarding
dimension when the rare variants are included in the
analysis, since only two variants at the SNP level reach
suggestive association and no SNP reaches genome-wide
significance. This contrasts with the findings obtained for
this dimension in the gene-based and pathway analyses,
which are notably more numerous than for the other
dimensions. We think this suggests a role for rare variants
in the hoarding dimension. We also believe that the
consistently observed higher heritability of this dimen-
sion, compared to the others9,10,89,90, could mostly be
explained by the influence of rare variants. Further
research is needed to reveal the genetic bases of the
hoarding dimension.
Although OCD symptom dimensions overcome the
unitary clinical diagnosis of OCD, subtyping OCD
according to overt clinical manifestations also presents
significant limitations. Due to methodological differences,
no concrete OCD dimensions classification system has
been universally accepted. Some authors argue that other
taxometric methods should be used to elucidate the
symptom dimensions in OCD, including age of onset,
comorbidities, or neuropsychological functioning in
combination with clinical manifestations. The lack of
significant associations among OCD symptom dimen-
sions and individual SNPs could reflect limited statistical
power due to the small sample size. Considering our total
sample size, the number of cases and controls for each
OCD dimension, a significance threshold of p < 2 × 10−7
(Bonferroni threshold for 258,000 SNPs analyzed) and a
risk allele frequency (MAF) of 0.1, our study has 80%
power to detect a relative risk (RR) of 3.5 and 5 (equiva-
lent to OR= 4.8 and OR= 9) for order and sexual/reli-
gious dimensions, respectively; for the three other OCD
dimensions, the detectable RR under these conditions is 4
(equivalent to OR= 6). A representation of the statistical
power achieved for different MAF and RR thresholds is
shown in Supplementary Fig. 1 (Fig. S1a–e). Furthermore,
we would have liked to consider the severity score for
each dimension in our analysis, in addition to their pre-
sence/absence, which would have been possible with a
larger sample. However, our sample was thoroughly
characterized phenotypically, and our results highlight
important differences in relation to the genetic bases, as
well as the genetic load of the different OCD dimensions.
In addition, rare variants are considered at gene-based
and pathway analyses, since this kind of analysis increases
the power of detecting small effects. The inclusion of rare
variants is important given the growing appreciation for
their importance in neuropsychiatric disorders91–93.
OCD is a highly heterogeneous disorder in terms of
symptom profile, comorbidity and underlying brain sub-
strate, which represents a challenge for understanding and
treating the disorder. This heterogeneity may confound
and contribute to mostly negative findings in current
genome-wide analysis studies, despite clear evidence for a
strong genetic component of the disorder based on twin
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and family studies, ranging from 40–65%. Therefore,
broad consensus has emerged for the need to explore
OCD not as a homogeneous diagnosis, but rather con-
sidering other phenomenological approaches that inves-
tigate more refined phenotypes. In this sense,
investigating genetic markers associated with different
OCD symptom dimensions could be a useful strategy to
begin disentangling the complex genetic vulnerability of
the disorder. A clearer identification of susceptibility
genes for OCD would translate into a better under-
standing of the etiology of the disorder and would help to
develop potentially targeted and specific treatment
approaches to improve the long-term outcome for OCD
patients.
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